share_log

JCRファーマ:MEDIPALとJCRは、ムコ多糖症IIIB型に対するJR-446の第I/II相試験の日本での臨床試験通知プロセスの完了を発表しました

JCR Pharmaceuticals: MEDIPAL and JCR have announced the completion of the clinical trial notification process for the phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB in Japan.

JPX ·  Jul 1 03:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more